Real world study of Invokana shows improved glucose control in type 2 diabetes, with data published in Current Medical Research and Opinion.- Janssen Pharma.
Janssen Pharmaceutical announced the results of a real-world study showing that adults with type 2 diabetes initiated on Invokana (canagliflozin) 300mg had significantly better blood glucose control, based on A1C goal attainment and reduction, compared to similar patients initiated on Farxiga (dapagliflozin) 10mg. Patients on Invokana were also less likely to discontinue treatment or switch to another medicine to treat their type 2 diabetes. Findings were recently published in Current Medical Research and Opinion.
In the analysis, which matched Invokana and dapagliflozin patients based on demographic and clinical characteristics including A1C, a significantly greater proportion of Invokana patients achieved the HEDIS A1C goal of less than 8.0 percent (70.8 vs. 59.1 percent, p=0.0001), as well as the ADA goal of less than 7.0 percent (36.7 vs. 25.1 percent, p<0.0001). analyzing data at six months after patients initiated the medications, the investigators found that patients on invokana 300mg had a 29 percent greater reduction in a1c compared to patients initiated on dapagliflozin 10mg. a significantly higher proportion of invokana patients than dapagliflozin patients achieved a1c less than 8.0 percent (primary endpoint): 70.8 percent vs. 59.1 percent; odds ratio (or) 1.60, 95 percent confidence interval (ci): 1.26, 2.04; p="0.0001." a significantly higher proportion of invokana patients than dapagliflozin patients achieved a1c less than 7.0 percent: 36.7 percent vs. 25.1 percent; or 1.75, ci: 1.34, 2.27; p><0.0001. average a1c levels were significantly lower in invokana vs. dapagliflozin patients: 7.57 percent vs. 7.85 percent, difference of -0.28 percent; p="0.0003.">0.0001.>0.0001).>
See: "A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin" Lawrence Blonde et al. Current Medical Research and Opinion posted online: 29 Mar 2018, Published online: 20 Apr 2018 https://doi.org/10.1080/03007995.2018.1458709
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)